Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

Jenny C. Chang, Eric C. Wooten, Anna Tsimelzon, Susan G. Hilsenbeck, M. Carolina Gutierrez, Richard M Elledge, Syed Mohsin, C. Kent Osborne, Gary C. Chamness, D. Craig Allred, Peter O'Connell

Research output: Contribution to journalArticle

692 Citations (Scopus)

Abstract

Background: Systemic chemotherapy for operable breast cancer substantially decreases the risk of death. Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel. Methods: We took core biopsy samples from primary breast tumours in 24 patients before treatment and then assessed tumour response to neoadjuvant docetaxel (four cycles, 100 mg/m2 daily for 3 weeks) by cDNA analysis of RNA extracted from biopsy samples using HgU95-Av2 GeneChip. Findings: From the core biopsy samples, we extracted sufficient total RNA (3-6 μg) for cDNA array analysis using HgU95-Av2 GeneChip. Differential patterns of expression of 92 genes correlated with docetaxel response (p=0.001). Sensitive tumours had higher expression of genes involved in cell cycle, cytoskeleton, adhesion, protein transport, protein modification, transcription, and stress or apoptosis; whereas resistant tumours showed increased expression of some transcriptional and signal transduction genes. In leave-one-out cross-validation analysis, ten of 11 sensitive tumours (90% specificity) and 11 of 13 resistant tumours (85% sensitivity) were correctly classified, with an accuracy of 88%. This 92-gene predictor had positive and negative predictive values of 92% and 83%, respectively. Correlation between RNA expression measured by the arrays and semiquantitative RT-PCR was also ascertained, and our results were validated in an independent set of six patients. Interpretation: If validated, these molecular profiles could allow development of a clinical test for docetaxel sensitivity, thus reducing unnecessary treatment for women with breast cancer.

Original languageEnglish (US)
Pages (from-to)362-369
Number of pages8
JournalLancet
Volume362
Issue number9381
DOIs
StatePublished - Aug 2 2003
Externally publishedYes

Fingerprint

docetaxel
Gene Expression Profiling
Breast Neoplasms
RNA
Neoplasms
Biopsy
Therapeutics
Gene Expression
Protein Transport
Oligonucleotide Array Sequence Analysis
Cytoskeleton
Transcriptome
Genes
Signal Transduction
Cell Cycle
Carrier Proteins
Complementary DNA
Apoptosis
Drug Therapy
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chang, J. C., Wooten, E. C., Tsimelzon, A., Hilsenbeck, S. G., Gutierrez, M. C., Elledge, R. M., ... O'Connell, P. (2003). Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, 362(9381), 362-369. https://doi.org/10.1016/S0140-6736(03)14023-8

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. / Chang, Jenny C.; Wooten, Eric C.; Tsimelzon, Anna; Hilsenbeck, Susan G.; Gutierrez, M. Carolina; Elledge, Richard M; Mohsin, Syed; Osborne, C. Kent; Chamness, Gary C.; Allred, D. Craig; O'Connell, Peter.

In: Lancet, Vol. 362, No. 9381, 02.08.2003, p. 362-369.

Research output: Contribution to journalArticle

Chang, JC, Wooten, EC, Tsimelzon, A, Hilsenbeck, SG, Gutierrez, MC, Elledge, RM, Mohsin, S, Osborne, CK, Chamness, GC, Allred, DC & O'Connell, P 2003, 'Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer', Lancet, vol. 362, no. 9381, pp. 362-369. https://doi.org/10.1016/S0140-6736(03)14023-8
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge RM et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 2;362(9381):362-369. https://doi.org/10.1016/S0140-6736(03)14023-8
Chang, Jenny C. ; Wooten, Eric C. ; Tsimelzon, Anna ; Hilsenbeck, Susan G. ; Gutierrez, M. Carolina ; Elledge, Richard M ; Mohsin, Syed ; Osborne, C. Kent ; Chamness, Gary C. ; Allred, D. Craig ; O'Connell, Peter. / Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. In: Lancet. 2003 ; Vol. 362, No. 9381. pp. 362-369.
@article{d5bf5d35670b4f60afb0ebe62de3fa93,
title = "Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer",
abstract = "Background: Systemic chemotherapy for operable breast cancer substantially decreases the risk of death. Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel. Methods: We took core biopsy samples from primary breast tumours in 24 patients before treatment and then assessed tumour response to neoadjuvant docetaxel (four cycles, 100 mg/m2 daily for 3 weeks) by cDNA analysis of RNA extracted from biopsy samples using HgU95-Av2 GeneChip. Findings: From the core biopsy samples, we extracted sufficient total RNA (3-6 μg) for cDNA array analysis using HgU95-Av2 GeneChip. Differential patterns of expression of 92 genes correlated with docetaxel response (p=0.001). Sensitive tumours had higher expression of genes involved in cell cycle, cytoskeleton, adhesion, protein transport, protein modification, transcription, and stress or apoptosis; whereas resistant tumours showed increased expression of some transcriptional and signal transduction genes. In leave-one-out cross-validation analysis, ten of 11 sensitive tumours (90{\%} specificity) and 11 of 13 resistant tumours (85{\%} sensitivity) were correctly classified, with an accuracy of 88{\%}. This 92-gene predictor had positive and negative predictive values of 92{\%} and 83{\%}, respectively. Correlation between RNA expression measured by the arrays and semiquantitative RT-PCR was also ascertained, and our results were validated in an independent set of six patients. Interpretation: If validated, these molecular profiles could allow development of a clinical test for docetaxel sensitivity, thus reducing unnecessary treatment for women with breast cancer.",
author = "Chang, {Jenny C.} and Wooten, {Eric C.} and Anna Tsimelzon and Hilsenbeck, {Susan G.} and Gutierrez, {M. Carolina} and Elledge, {Richard M} and Syed Mohsin and Osborne, {C. Kent} and Chamness, {Gary C.} and Allred, {D. Craig} and Peter O'Connell",
year = "2003",
month = "8",
day = "2",
doi = "10.1016/S0140-6736(03)14023-8",
language = "English (US)",
volume = "362",
pages = "362--369",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9381",

}

TY - JOUR

T1 - Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

AU - Chang, Jenny C.

AU - Wooten, Eric C.

AU - Tsimelzon, Anna

AU - Hilsenbeck, Susan G.

AU - Gutierrez, M. Carolina

AU - Elledge, Richard M

AU - Mohsin, Syed

AU - Osborne, C. Kent

AU - Chamness, Gary C.

AU - Allred, D. Craig

AU - O'Connell, Peter

PY - 2003/8/2

Y1 - 2003/8/2

N2 - Background: Systemic chemotherapy for operable breast cancer substantially decreases the risk of death. Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel. Methods: We took core biopsy samples from primary breast tumours in 24 patients before treatment and then assessed tumour response to neoadjuvant docetaxel (four cycles, 100 mg/m2 daily for 3 weeks) by cDNA analysis of RNA extracted from biopsy samples using HgU95-Av2 GeneChip. Findings: From the core biopsy samples, we extracted sufficient total RNA (3-6 μg) for cDNA array analysis using HgU95-Av2 GeneChip. Differential patterns of expression of 92 genes correlated with docetaxel response (p=0.001). Sensitive tumours had higher expression of genes involved in cell cycle, cytoskeleton, adhesion, protein transport, protein modification, transcription, and stress or apoptosis; whereas resistant tumours showed increased expression of some transcriptional and signal transduction genes. In leave-one-out cross-validation analysis, ten of 11 sensitive tumours (90% specificity) and 11 of 13 resistant tumours (85% sensitivity) were correctly classified, with an accuracy of 88%. This 92-gene predictor had positive and negative predictive values of 92% and 83%, respectively. Correlation between RNA expression measured by the arrays and semiquantitative RT-PCR was also ascertained, and our results were validated in an independent set of six patients. Interpretation: If validated, these molecular profiles could allow development of a clinical test for docetaxel sensitivity, thus reducing unnecessary treatment for women with breast cancer.

AB - Background: Systemic chemotherapy for operable breast cancer substantially decreases the risk of death. Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel. Methods: We took core biopsy samples from primary breast tumours in 24 patients before treatment and then assessed tumour response to neoadjuvant docetaxel (four cycles, 100 mg/m2 daily for 3 weeks) by cDNA analysis of RNA extracted from biopsy samples using HgU95-Av2 GeneChip. Findings: From the core biopsy samples, we extracted sufficient total RNA (3-6 μg) for cDNA array analysis using HgU95-Av2 GeneChip. Differential patterns of expression of 92 genes correlated with docetaxel response (p=0.001). Sensitive tumours had higher expression of genes involved in cell cycle, cytoskeleton, adhesion, protein transport, protein modification, transcription, and stress or apoptosis; whereas resistant tumours showed increased expression of some transcriptional and signal transduction genes. In leave-one-out cross-validation analysis, ten of 11 sensitive tumours (90% specificity) and 11 of 13 resistant tumours (85% sensitivity) were correctly classified, with an accuracy of 88%. This 92-gene predictor had positive and negative predictive values of 92% and 83%, respectively. Correlation between RNA expression measured by the arrays and semiquantitative RT-PCR was also ascertained, and our results were validated in an independent set of six patients. Interpretation: If validated, these molecular profiles could allow development of a clinical test for docetaxel sensitivity, thus reducing unnecessary treatment for women with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0042125511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042125511&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)14023-8

DO - 10.1016/S0140-6736(03)14023-8

M3 - Article

VL - 362

SP - 362

EP - 369

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9381

ER -